Sarah Lamarca
Psychiatric/Mental Health · Sandusky, OHNPI 1689150278
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $53,833 of the $70,781 with a category attached, or 76.1%. 17 manufacturers reported payments, led by Teva Pharmaceuticals USA, Inc. at 54.9% of the total. 2025 is the largest year on record at $31,387, more than ten times the $141 reported in 2021. Among psychiatric/mental health clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 400 payments — averaging $176.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$39K
- AbbVie$19K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$11K
- Alkermes, Inc.$681
- Otsuka America Pharmaceutical, Inc.$498
- Indivior Inc.$360
- plus $1K from 11 others
What the payments were for
- Consulting fees$2,5004%
- Speaking & faculty fees$53,83376%
- Travel & lodging$5,2967%
- Food & beverage$8,92913%
- Education$2230%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 120 | $38,835 |
| AbbVie | 69 | $18,507 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 48 | $10,544 |
| Alkermes, Inc. | 36 | $681 |
| Otsuka America Pharmaceutical, Inc. | 39 | $498 |
| Indivior Inc. | 23 | $360 |
| Neurocrine Biosciences, Inc. | 17 | $350 |
| Axsome Therapeutics, Inc. | 13 | $348 |
| Johnson & Johnson | 15 | $303 |
| E.r. Squibb & Sons, L.L.C. | 7 | $114 |
| Sunovion Pharmaceuticals Inc. | 5 | $84 |
| Lundbeck LLC | 3 | $64 |
| Vanda Pharmaceuticals Inc. | 1 | $28 |
| Sage Therapeutics, LLC | 1 | $19 |
| Braeburn Inc. | 1 | $17 |
| Corium, LLC | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UZEDY$20,124
- VRAYLAR$17,207
- Austedo XR$14,946
- CAPLYTA$9,259
- LYBALVI$457
How this compares
$70,781 in reported general payments places this provider in the 95th percentile of 1,808 psychiatric/mental health providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 83 | $257,829 |
| Austedo XrDeutetrabenazine | 11 | $116,368 |
| RexultiBrexpiprazole | 52 | $78,730 |
| Lurasidone Hcl | 116 | $61,630 |
| VraylarCariprazine Hcl | 39 | $54,418 |
| AristadaAripiprazole Lauroxil | 21 | $50,328 |
| Abilify MaintenaAripiprazole | 17 | $45,320 |
| CaplytaLumateperone Tosylate | 26 | $44,494 |
| LybalviOlanzapine/Samidorphan Malate | 21 | $36,799 |
| UzedyRisperidone | 13 | $33,039 |
| TrintellixVortioxetine Hydrobromide | 42 | $26,868 |
| FetzimaLevomilnacipran Hcl | 32 | $18,538 |
| VivitrolNaltrexone Microspheres | 12 | $17,417 |
| AuvelityDextromethorphan Hbr/Bupropion | 11 | $15,550 |
| Aripiprazole | 163 | $13,510 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $303 | $257,82983 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Uzedy | $38,835 | $149,40724 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $498 | $124,05069 claims |
| Alkermes, Inc.Aristada, Lybalvi, Vivitrol | $681 | $104,54454 claims |
| AbbVieVraylar, Fetzima | $18,507 | $72,95671 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $10,544 | $44,49426 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $14 | $26,86842 claims |
| Axsome Therapeutics, Inc.Auvelity | $348 | $15,55011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,808 psychiatric/mental health providers in Ohio.
Other psychiatric/mental health in Sandusky
- Crystal TravisJackson$333K
- Kristina RoweIronton$253K
- Patricia SparksPortsmouth$210K
- Mary HallWarren$195K
- Kassandra KornbauCanfield$170K
- Steven MatesDayton$121K
- Robert ParsonsYoungstown$119K
- Chriscia BaneChillicothe$115K
- Rachael McLaughlinMaple Heights$114K
- Danielle MorroneCanfield$94K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.